TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients' needs, now and in the future.

We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets.

We operate our business through three segments: United States, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars and over-the-counter ("OTC") products, as well as innovative medicines. This structure enables strong alignment and integration between operations, commercial regions, R&D, and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas.

Last close 39.41 2026-10-23
Market cap $45.92B 2026-06-30 share count
52-week range 19.23 - 42.02

TEVA is a depositary receipt: one TEVA stands for 1 share of this company, per the cover page of its latest 10-K. The market cap and the multiples above are stated per receipt; the statements below, including EPS, are as filed and are per underlying share.

Valuation FY2025 figures against the last close

P/S2.7x
P/E32.6x
P/FCF40.0x
EV/EBITDA17.1x
Dividend yield—
Diluted EPS1.21

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $17.26B$16.54B$15.85B$14.93B$15.88B$16.66B$16.89B$18.27B$21.85B$21.90B
Cost of revenue $8.32B$8.48B$8.20B$7.95B$8.28B$8.93B$9.35B$9.97B$11.24B$10.25B
Gross profit $8.94B$8.06B$7.64B$6.97B$7.59B$7.73B$7.54B$8.30B$10.62B$11.65B
R&D ———$98.0M———$114.0M$175.0M$422.0M
SG&A $1.29B$1.16B$1.16B$1.18B$1.10B$1.17B$1.19B$1.30B$1.45B$1.39B
Operating income $2.16B-$303.0M$433.0M-$2.20B$1.72B-$3.57B-$443.0M-$1.64B-$17.48B$2.15B
Interest expense $916.0M$1.00B$1.03B$930.0M$891.0M$901.0M$822.0M$920.0M$875.0M$546.0M
Pre-tax income $1.22B-$1.28B-$624.0M-$3.16B$658.0M-$4.41B-$1.26B-$2.60B-$18.38B$824.0M
Income tax $180.0M$676.0M$7.0M$643.0M$211.0M$168.0M$278.0M$195.0M$1.93B$521.0M
Net income $1.41B-$1.64B-$559.0M-$2.45B$417.0M-$3.99B-$999.0M-$2.15B-$16.27B$329.0M
EPS, basic 1.23-1.45-0.50-2.200.38-3.64-0.91-2.35-16.260.07
EPS, diluted 1.21-1.45-0.50-2.200.38-3.64-0.91-2.35-16.260.07
Shares, diluted (wtd. avg.) 1.16B1.13B1.12B1.11B1.11B1.09B1.09B1.02B1.02B961

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $3.56B$3.30B$3.23B$2.83B$2.20B$2.18B$1.98B$1.78B$963.0M$988.0M
Receivables $3.71B$3.06B$3.41B$3.70B$4.53B$4.58B$5.68B$5.82B$7.13B—
Inventory $3.18B$3.01B$4.02B$3.83B$3.82B$4.40B$4.42B$4.73B$4.92B—
Total current assets $13.95B$12.55B$12.48B$12.05B$12.57B$13.01B$13.46B$13.79B$15.38B—
Property, plant and equipment $4.08B$4.58B$5.75B$5.74B$5.98B$6.30B$6.44B$6.87B$7.67B—
Goodwill $16.00B$15.15B$17.18B$17.18B$17.63B$20.62B$24.85B$24.92B$28.41B$44.41B
Other intangibles $3.78B$4.42B$5.39B$6.27B$7.47B$8.92B$11.23B$14.01B$17.64B—
Total assets $40.75B$39.33B$43.48B$45.93B$47.67B$50.64B$57.47B$60.68B$70.61B—
Accounts payable $225.0M$158.0M$108.0M———$1.72B$1.85B$2.07B—
Short-term debt $1.80B$1.76B$1.65B$2.09B$1.40B$2.67B$1.83B$1.70B$2.88B—
Total current liabilities $13.46B$12.80B$12.25B$11.47B$11.03B$13.16B$13.67B$14.32B$17.92B—
Total liabilities $32.83B$33.61B$35.35B$36.12B$36.42B$39.58B$42.41B$44.89B$51.87B—
Retained earnings -$13.76B-$15.17B-$13.53B-$11.73B-$10.53B-$10.95B-$6.96B-$5.96B-$3.80B—
Total equity $7.91B$5.37B$8.13B$8.60B$11.24B$11.06B$15.06B$15.79B$18.75B$34.99B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.65B$1.25B$1.37B$1.59B$798.0M$1.22B$748.0M$2.45B$2.23B$3.89B
Depreciation and amortisation $421.0M$471.0M$537.0M$576.0M$528.0M$537.0M$609.0M$676.0M$632.0M$501.0M
Stock-based compensation $157.0M$123.0M$121.0M$124.0M$119.0M$129.0M$119.0M$155.0M$133.0M$124.0M
Capital expenditure $501.0M$498.0M$526.0M$548.0M$562.0M$578.0M$525.0M$651.0M$874.0M$901.0M
Investing cash flow $737.0M$792.0M$968.0M$656.0M$1.52B$863.0M$1.35B$1.87B$3.45B-$34.41B
Financing cash flow -$2.15B-$1.79B-$1.91B-$1.49B-$2.17B-$1.89B-$1.93B-$3.35B-$5.75B$25.22B
Dividends paid ———————$12.0M$901.0M$1.30B
Buybacks —————$1.0M$6.0M$4.0M$0$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-034532.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20B -10B 0 10B 20B 30B Revenue, FY2016: 21.9B Gross profit, FY2016: 11.7B Net income, FY2016: 329M Revenue, FY2017: 21.9B Gross profit, FY2017: 10.6B Net income, FY2017: -16.3B Revenue, FY2018: 18.3B Gross profit, FY2018: 8.3B Net income, FY2018: -2.1B Revenue, FY2019: 16.9B Gross profit, FY2019: 7.5B Net income, FY2019: -999M Revenue, FY2020: 16.7B Gross profit, FY2020: 7.7B Net income, FY2020: -4B Revenue, FY2021: 15.9B Gross profit, FY2021: 7.6B Net income, FY2021: 417M Revenue, FY2022: 14.9B Gross profit, FY2022: 7B Net income, FY2022: -2.4B Revenue, FY2023: 15.8B Gross profit, FY2023: 7.6B Net income, FY2023: -559M Revenue, FY2024: 16.5B Gross profit, FY2024: 8.1B Net income, FY2024: -1.6B Revenue, FY2025: 17.3B Gross profit, FY2025: 8.9B Net income, FY2025: 1.4B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $21.90B $21.85B $18.27B $16.89B $16.66B $15.88B $14.93B $15.85B $16.54B $17.26B
Gross profit $11.65B $10.62B $8.30B $7.54B $7.73B $7.59B $6.97B $7.64B $8.06B $8.94B
Net income $329.0M -$16.27B -$2.15B -$999.0M -$3.99B $417.0M -$2.45B -$559.0M -$1.64B $1.41B

Recent filings and events

  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%